Skip to main content

Gloperba Disease Interactions

There are 7 disease interactions with Gloperba (colchicine).

Major

Colchicine (applies to Gloperba) bone marrow suppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

The use of colchicine should be used with caution in patients with bone marrow suppression. Patients on long term therapy may require periodic blood counts.

References

  1. Ferrannini E, Pentimone F (1984) "Marrow aplasia following colchicine treatment for gouty arthritis." Clin Exp Rheumatol, 2, p. 173-5
  2. Liu YK, Hymowitz R, Carroll MG (1978) "Marrow aplasia induced by colchicine. A case report." Arthritis Rheum, 21, p. 731-5
  3. Neuss MN, McCallum RM, Brenckman WD, Silberman HR (1986) "Long-term colchicine administration leading to colchicine toxicity and death." Arthritis Rheum, 29, p. 448-9
  4. Finklestein M, Goldman L, Grace ND, Foley M, Randall N (1987) "Granulocytopenia complicating colchicine therapy for primary biliary cirrhosis." Gastroenterology, 93, p. 1231-5
  5. Stanley MW, Taurog JD, Snover DC (1984) "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol, 2, p. 167-71
  6. Vedia C, Mascort JJ, Carrasco I, Olive A (1993) "Colchicine and thrombopenia." Clin Exp Rheumatol, 11, p. 458
  7. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW (1991) "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol, 18, p. 264-9
  8. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
View all 8 references
Major

Colchicine (applies to Gloperba) cardiac dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

The use of colchicine should be used with caution in patients with cardiac dysfunction. The possibility of cumulative effects of colchicine is increased in these patients.

References

  1. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
Major

Colchicine (applies to Gloperba) DIC

Major Potential Hazard, High plausibility. Applicable conditions: Disseminated Intravascular Coagulation

Colchicine should be used with caution in patients with disseminated intravascular coagulation. Debilitated patients have an increased risk of developing colchicine toxicity.

References

  1. Vedia C, Mascort JJ, Carrasco I, Olive A (1993) "Colchicine and thrombopenia." Clin Exp Rheumatol, 11, p. 458
  2. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
Major

Colchicine (applies to Gloperba) electrolyte disturbances

Major Potential Hazard, High plausibility. Applicable conditions: Hyponatremia, Hypokalemia, Electrolyte Abnormalities

Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.

References

  1. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
Major

Colchicine (applies to Gloperba) liver disease

Major Potential Hazard, High plausibility.

The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). Caution is recommended when prescribing colchicine to these patients.

References

  1. Zifroni A, Schaffner F (1991) "Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy." Hepatology, 14, p. 990-3
  2. Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E (1992) "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol, 19, p. 494-6
  3. Leighton JA, Bay MK, Maldonado AL, Schenker S, Speeg KV (1991) "Colchicine clearance is impaired in alcoholic cirrhosis." Hepatology, 14, p. 1013-5
  4. Stanley MW, Taurog JD, Snover DC (1984) "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol, 2, p. 167-71
  5. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L (1987) "A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report." J Hepatol, 5, p. 1-7
  6. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
  7. Kocak N, Yuce A, Gurakan F, Ozen H, Gogus S, Kale G, Caglar M (1996) "Colchicine in the treatment of hepatic fibrosis in children." Am J Gastroenterol, 91, p. 179-80
View all 7 references
Major

Colchicine (applies to Gloperba) renal dysfunction

Major Potential Hazard, High plausibility.

Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Colchicine dosing must be individualized according to the patient's renal function. Caution must be exercised when colchicine therapy is instituted in these patients. Monitoring creatinine function is recommended in patients on long term therapy.

References

  1. Older SA, Finbloom DS, Pezeshkpour GH (1992) "Colchicine myoneuropathy and renal dysfunction." Ann Rheum Dis, 51, p. 1343-4
  2. Said R, Hamzeh Y, Tarawneh M, el-Khateeb M, Abdeen M, Shaheen A (1989) "Rapid progressive glomerulonephritis in patients with familial Mediterranean fever." Am J Kidney Dis, 14, p. 412-6
  3. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW (1991) "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol, 18, p. 264-9
  4. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company
View all 4 references
Moderate

Colchicine (applies to Gloperba) rhabdomyolysis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Caution must be exercised when colchicine therapy is instituted in these patients.

References

  1. (2001) "Product Information. Colchicine (colchicine)." Lilly, Eli and Company

Gloperba drug interactions

There are 268 drug interactions with Gloperba (colchicine).

Gloperba alcohol/food interactions

There is 1 alcohol/food interaction with Gloperba (colchicine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer